化工儀器網(wǎng)
資料下載
測量應用案例-20200807
閱讀：147 發(fā)布時間：2020-8-20| 提 供 商 | 美國布魯克海文儀器公司 | 資料大小 | 7.5MB |
|---|---|---|---|
| 資料圖片 | 下載次數(shù) | 24次 | |
| 資料類型 | PDF 文件 | 瀏覽次數(shù) | 147次 |
| 免費下載 | 點擊下載 |
文獻名： Nanoengineered immunosuppressive therapeutics modulating M1/M2 macrophages into the balanced status for enhanced idiopathic pulmonary fibrosis therapy
作者： Xin Chang,‡a Lei Xing,‡abcd Yi Wang,a Tian-Jiao Zhou,a Li-Jun Shena and Hu-Lin Jiang abcd
a State Key Laboratory of Natural Medicines, China Pharmaceutical University, China
b Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, China
c Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, China
d Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, China
摘要：Effective treatment in clinic for idiopathic pulmonary fibrosis (IPF) remains a challenge due to low drug accumulation in lungs and imbalanced polarization of pro/anti-inflammatory macrophages (M1/M2 macrophages). Herein, a novel endogenous cell-targeting nanoplatform (PNCE) is developed for enhanced IPF treatment efficacy through modulating M1/M2 macrophages into the balanced status to suppress fibroblast over-activation. Notably, PNCE loaded with nintedanib (NIN) and colchicine (COL) can firstly target endogenous monocyte-derived multipotent cells (MOMCs) and then be effectively delivered into IPF lungs due to the homing ability of MOMCs, and detached sensitively from MOMCs by matrix metalloproteinases-2 (MMP-2) over-expressed in IPF lungs. After PNCE selectively accumulated within fibrosis foci, COL can mildly modulate the polarization of M1 macrophages into M2 macrophages to balance innate immune responses, which can enhance the suppressing effect of NIN on fibroblast activation, further improving the IPF therapy. Altogether, PNCE has two collaborative steps including the inhibition of innate immune responses accompanied by the decrease of fibroblast populations in IPF lungs, achieving a stronger and excellent anti-fibrotic efficacy both in vitro and in vivo. This endogenous cell-based engineered liposomal nanoplatform not only allows therapeutic drugs to take effect selectively in vivo, but also provides an alternative strategy for an enhanced curative effect by modulating innate immune responses in IPF therapy.